Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Oxid Med Cell Longev ; 2022: 6110226, 2022.
Article in English | MEDLINE | ID: mdl-35571254

ABSTRACT

Background: Aging is a major risk factor for a range of chronic diseases. Oxidative stress theory of aging has been previously proposed as one of the mechanisms responsible for the age-related decline in organ/tissue function and the development of age-related diseases. Urine contains rich biological information on the health status of every major organ system and can be an important noninvasive source for biomarkers of systemic oxidative stress in aging. Aims: The objective of this cross-sectional study was to validate a novel panel of urinary oxidative stress biomarkers. Methods: Nucleic acid oxidation adducts and oxidative damage markers of lipids and proteins were assessed in urine samples from nondiabetic and currently nonsmoking subjects (n = 198) across different ages (20 to 89 years old). Urinary parameters and chronological age were correlated then the biological age of enrolled individuals was determined from the urinary oxidative stress markers using the algorithm of Klemera and Doubal. Results: Our findings showed that 8-oxo-7,8-deoxyguanosine (8-oxoG), 8-oxo-7,8-dihydroguanosine (8-OHdG), and dityrosine (DTyr) positively correlated with chronological age, while the level of an F2-isoprostane (iPF2 α-VI) correlated negatively with age. We found that 8-oxoG, DTyr, and iPF2 α-VI were significantly higher among accelerated agers compared to nonaccelerated agers and that a decision tree model could successfully identify accelerated agers with an accuracy of >92%. Discussion. Our results indicate that 8-oxoG and iPF2 α-VI levels in the urine reveal biological aging. Conclusion: Assessing urinary biomarkers of oxidative stress may be an important approach for the evaluation of biological age by identifying individuals at accelerated risk for the development of age-related diseases.


Subject(s)
Aging , Oxidative Stress , Adult , Aged , Aged, 80 and over , Biomarkers/urine , Cross-Sectional Studies , Deoxyguanosine/urine , Humans , Middle Aged , Prospective Studies , Young Adult
2.
J Gerontol A Biol Sci Med Sci ; 75(6): 1167-1175, 2020 05 22.
Article in English | MEDLINE | ID: mdl-31282538

ABSTRACT

BACKGROUND: Standardization of performance-based physical function measures that are reliable and responsive to intervention is necessary for efficacy trials of function promoting anabolic therapies (FPTs). Herein, we describe a standardized method of measuring stair climbing power (SCP) and evaluate its ability to assess improvements in physical function in response to an FPT (testosterone) compared to gait speed. METHODS: We used a 12-step SCP test with and without carrying a load (loaded, LSCP or unloaded, USCP) in two testosterone trials in older men. SCP was determined from mass, total step-rise, and time of ascent measured with an electronic timing system. Associations between SCP and leg press performance (strength and power), testosterone levels, and gait speed were assessed. Test-retest reliability was evaluated using interclass correlation and Bland-Altman analyses. RESULTS: Baseline SCP was negatively associated with age and positively with leg strength and power and gait speed. Both tests of SCP were safe and showed excellent reliability (intra-class correlation 0.91-0.97 in both cohorts). Changes in testosterone concentrations were associated with changes in USCP and LSCP, but not gait speed in mobility-limited men. Changes in leg press performance were associated with SCP in both trials. CONCLUSIONS: Both USCP and LSCP are safe and have high test-retest reliability. Compared to gait speed, SCP is associated more robustly with leg press performance and is sensitive to testosterone therapy. The LSCP might be a more responsive outcome than gait speed to evaluate the efficacy of FPT in randomized trials.


Subject(s)
Exercise Test , Stair Climbing/physiology , Administration, Cutaneous , Aged , Exercise Test/methods , Exercise Test/standards , Gels , Geriatric Assessment/methods , Humans , Male , Physical Fitness , Randomized Controlled Trials as Topic/methods , Randomized Controlled Trials as Topic/standards , Reproducibility of Results , Stair Climbing/drug effects , Testosterone/administration & dosage , Testosterone/therapeutic use , Treatment Outcome
3.
Drugs Aging ; 36(11): 981-989, 2019 11.
Article in English | MEDLINE | ID: mdl-31595418

ABSTRACT

The number of older adults over 65 years of age is expected to increase to almost 100 million in the US by 2050, more than double the current figure of 46 million. Advanced age is associated with increased frailty among older Americans and often leads to increased disability, hospitalization, institutionalization, and, eventually, mortality. In search of means to improve age-related risks for adverse health outcomes, the question of restoring diminishing sex hormones has gathered much interest and has led to the practice of sex hormone replacement therapies in older men. Recent data suggest that androgen prescription rates in the US for men older than 60 years of age quadrupled from the years 2001 to 2011. While prescription sales of testosterone have increased from $150 million in 2000 to $1.8 billion in 2011, a significant portion of men prescribed testosterone replacement therapy did not meet the laboratory criteria for hypogonadism. While some clinical trials reported an association between testosterone insufficiency in older men and increased risk of death, the exact effects and consequences of testosterone replacement therapy, specifically in older men, remain unclear. This review is aimed at discussing the possible benefits and complications of testosterone replacement therapy in older men over 60 years of age.


Subject(s)
Androgens/therapeutic use , Hormone Replacement Therapy , Hypogonadism/drug therapy , Testosterone/therapeutic use , Aged , Hormone Replacement Therapy/adverse effects , Hormone Replacement Therapy/methods , Humans , Hypogonadism/metabolism , Male , Middle Aged , Risk Assessment , Treatment Outcome
4.
Nutr Res ; 29(12): 846-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19963157

ABSTRACT

The antiglycemic effects of vinegar have been known for more than a century and have been demonstrated in animal as well as human studies. Although the exact mechanism of vinegar action is not known, several possibilities have been proposed including suppression of disaccharidase activity, delayed gastric emptying, enhanced glucose uptake in the periphery and conversion to glycogen, and increased satiety. We hypothesized that by suppressing endogenous insulin secretion, we could estimate the glucose absorption rate from an oral carbohydrate load and determine the effects of vinegar ingestion on this rate. To do so, 5 subjects had 4 studies at 1-week intervals, randomly receiving placebo twice (60 mL water) and vinegar twice (20 mL apple cider vinegar, 40 mL water), followed 2 minutes later by a meal of mashed potatoes (0.75 g carbohydrate per kilogram body weight) that was consumed over 20 minutes. At the beginning of the meal, an oral octreotide/insulin suppression test (25-microg bolus octreotide; 180 minute infusion 5 mU/m(2) body surface area per minute regular human insulin, and 0.5 microg/min octreotide) was begun. Blood samples for insulin and glucose were drawn at 20-minute intervals. The oral octreotide/insulin suppression test suppressed endogenous insulin secretion for the first 100 minutes of the study. During this time, the rate of rise of glucose was modestly but significantly (P = .01) greater after vinegar ingestion compared to placebo, suggesting that vinegar does not act to decrease glycemia by interference with enteral carbohydrate absorption.


Subject(s)
Acetic Acid/metabolism , Dietary Carbohydrates/metabolism , Hypoglycemic Agents/metabolism , Intestinal Absorption , Adult , Aged , Area Under Curve , Blood Glucose/analysis , Diagnostic Techniques, Endocrine , Female , Humans , Infusions, Intravenous , Insulin/administration & dosage , Insulin/blood , Insulin/pharmacology , Insulin Antagonists/pharmacology , Male , Middle Aged , Octreotide/pharmacology
5.
Free Radic Biol Med ; 35(10): 1301-9, 2003 Nov 15.
Article in English | MEDLINE | ID: mdl-14607529

ABSTRACT

To assess novel liquid chromatography/mass spectrometric methods for measuring oxidative damage to nucleic acids and lipids, we compared urinary excretion of 8-hydroxy-2'-deoxyguanosine (8-OHdG), 5-hydroxymethyl-2'-deoxyuridine (5-OHmU), and 8-hydroxyguanosine (8-OxoG), and an isoprostane, 8-iso-prostaglandin F(2)alpha (IsopF(2)alpha) in 234 healthy men (n = 113) and women (n = 121), 80 current smokers, 96 never-smokers), and 58 ex-smokers (no tobacco use for 3 years). The 8-OHdG and 8-OxoG did not differ significantly by group; 5-OHmU was higher in smokers, compared with ex- (p <.003) and never- (p <.0001) smokers and in ex- vs. never-smokers (p =.014) at, respectively, 13.5 +/- 0.7, 11.3 +/- 1.0, and 8.7 +/- 0.3 microg/g creatinine. IsopF(2)alpha was higher in smokers, compared with ex- (p =.007) and never-smokers (p <.0001) and in ex- vs. never- smokers (p =.002) at, respectively, 1.1 +/- 0.10; 0.74 +/- 0.07, and 0.51 +/- 0.04 microg/g creatinine. There were significant correlations among all three nucleic acid adducts and between IsopF(2)alpha and both 5-OHmU and 8-OHdG. Many smokers and ex-smokers had high levels of either 5-OHmU excretion or IsopF(2)alpha excretion, but not both. We conclude that 5-OHmU and IsopF(2)alpha are more discriminating of oxidative stress from tobacco smoke than the other two compounds measured. Whether characteristic patterns of excretion of these indicators forecast differential disease risk should be explored in future research.


Subject(s)
DNA Adducts/metabolism , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/urine , Dinoprost/urine , Guanosine/analogs & derivatives , Guanosine/urine , Smoking/metabolism , Thymidine/analogs & derivatives , Thymidine/urine , 8-Hydroxy-2'-Deoxyguanosine , Adult , Age Distribution , Aged , Aged, 80 and over , Chromatography, Liquid , Dinoprost/analogs & derivatives , Female , Humans , Male , Mass Spectrometry , Middle Aged , Oxidation-Reduction , Oxidative Stress , Sex Distribution , Smoking/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...